Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

G. Aaron Hobbs

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4751-9681; OpenAlex author ID A5068312423. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
91
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 6 papers

Papers 16

  1. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2026.117627↗
  2. PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-24-4501↗
  3. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… First author DOI 10.1158/0008-5472.can-25-0018↗
  4. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1835↗
  5. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Last author DOI 10.1158/0008-5472.can-25-2630↗
  6. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-1181↗
  7. Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.3390/biom15050645↗
  8. HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41418-024-01310-9↗
  9. A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Co-author DOI 10.3390/antib13040101↗
  10. KRAS G12R-Independent Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1007/978-3-030-94004-1_11↗
  11. STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.26508/lsa.202201460↗
  12. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2021.109291↗
  13. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.05.010↗
  14. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  15. Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-1006↗
  16. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗

Closest collaborators

The 25 strongest of 91 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Channing J. Der · 10 shared papers, 2019–2026 · strength 1.52
  2. Rachel A. Burge · 4 shared papers, 2024–2026 · strength 0.89
  3. Adrienne D. Cox · 6 shared papers, 2019–2026 · strength 0.70
  4. Andrew M. Waters · 6 shared papers, 2019–2026 · strength 0.70
  5. David F. Kashatus · 3 shared papers, 2024–2026 · strength 0.66
  6. Andrew J. Aguirre · 5 shared papers, 2020–2026 · strength 0.63
  7. Clint A. Stalnecker · 5 shared papers, 2019–2026 · strength 0.63
  8. Thomas B. McFall · 3 shared papers, 2026 · strength 0.62
  9. John P O'Bryan · 3 shared papers, 2024–2025 · strength 0.60
  10. Craig M. Goodwin · 4 shared papers, 2020–2026 · strength 0.57
  11. Denis C. Guttridge D · 3 shared papers, 2022–2026 · strength 0.56
  12. Bjoern Papke · 5 shared papers, 2019–2026 · strength 0.49
  13. J. Nathaniel Diehl · 5 shared papers, 2019–2026 · strength 0.49
  14. Jennifer E. Klomp · 5 shared papers, 2019–2026 · strength 0.49
  15. Todd W. Bauer · 2 shared papers, 2026 · strength 0.49
  16. A. Cole Edwards · 3 shared papers, 2021–2026 · strength 0.49
  17. Reeder M. Robinson · 2 shared papers, 2024–2025 · strength 0.43
  18. Benjamin N. Christopher · 2 shared papers, 2024–2025 · strength 0.43
  19. Nathan G. Dolloff · 2 shared papers, 2024–2025 · strength 0.43
  20. Kirsten L. Bryant · 4 shared papers, 2019–2026 · strength 0.43
  21. Tikvah K. Hayes · 4 shared papers, 2019–2026 · strength 0.41
  22. Christabelle Rajesh · 2 shared papers, 2026 · strength 0.41
  23. Nikki K. Lytle · 2 shared papers, 2026 · strength 0.41
  24. Yongwoo David Seo · 2 shared papers, 2026 · strength 0.41
  25. Daniel Dorbin · 2 shared papers, 2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.